Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 6/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13754688 | 0.79 | PTGES (0.44) | PTGESACACBGRM5 | |
| SCHEMBL4483751 | 0.77 | PTGES (0.48) | PTGESACACBSLC2A1 | |
| SCHEMBL4475705 | 0.76 | GRM5 (0.33) | PTGDR2GRM5NR3C2 | |
| SCHEMBL4475363 | 0.76 | NPC1 (0.40) | GRM5SLC2A1MEN1KMT2AABL1 | |
| SCHEMBL4493461 | 0.74 | DAO (0.36) | PTGESSLC2A1NR3C2 | |
| SCHEMBL4483764 | 0.74 | PTGS2 (0.40) | PTGDR2ACACBGRM5NR3C2TRPV3 | |
| SCHEMBL9262778 | 0.73 | TYMP (0.51) | SLC2A1MEN1KMT2A | |
| SCHEMBL9266330 | 0.72 | TYMP (0.50) | SLC2A1MEN1KMT2A | |
| SCHEMBL4490980 | 0.70 | SCD (0.45) | SLC2A1 | |
| SCHEMBL4469233 | 0.70 | SLC2A1 (0.52) | PTGESGRM5SLC2A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | claimed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | claimed |
| US-7579353-B2 | Pyridinone derivatives against malaria | GLAXO GROUP LIMITED (GB) | 2009-08-25 | — | — | US | disclosed |
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287461-A1 | Pyridinone Derivatives Against Malaria | G6PD, PNPO, PLPBP | PTGES 842/4885PTGDR2 1148/4885ACACB 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.